Research summary ·
Emerging Effects of Glucagon-Like Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors on Male Sexual Hormones and Behaviors: Systematic Review and Meta-Analysis.
Written based on 1 research study on PubMed, searched on 5 Nov 2026.
What was studied
This review pooled results from earlier studies. It looked at people with overweight or obesity, some with diabetes. The drug groups checked were GLP1-RA drugs and SGLT2i drugs. The team asked how these drugs affect male sex hormones and sex life. They searched the Medline database from 1969 to August 2025. Both trials and studies that only watched people were included.
What they found
Studies on GLP1-RA drugs had 375 people in total. Studies on SGLT2i drugs had only 52 people. Both drug groups helped body makeup and metabolic health. Erection function got better with both kinds of drug. Only GLP1-RA drugs raised testosterone and the hormones that drive it. This rise did not depend on the weight that was lost. The authors think these drugs may act right on the hormone system. Testosterone treatment did better than GLP1-RA drugs for orgasm and sex satisfaction.
What it means for patients
The authors say the data support GLP1-RA drugs for sex problems. They say this applies to obese men with erection problems. They say these drugs may also help the heart problems linked to this. In some cases, doctors may join testosterone treatment with GLP1-RA drugs. The data on SGLT2i drugs are too few for firm views.
Why it is not certain yet
The SGLT2i results come from only 52 people. The authors say these data are too limited. The review mixed trials with studies that only watched people. Only one database, Medline, was searched. The abstract does not say how long people were followed. A review can only be as good as the studies in it.
Source
Emerging Effects of Glucagon-Like Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors on Male Sexual Hormones and Behaviors: Systematic Review and Meta-Analysis.
PubMed · PMID 42011503We restate facts from the source record in our own words. The original wording belongs to its publisher.
This page is not medical advice. Talk to your doctor about your own care.
Back to Obesity publications